AbbottABT
ABT
About: Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Employees: 114,000
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 11 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
187% more first-time investments, than exits
New positions opened: 301 | Existing positions closed: 105
25% more call options, than puts
Call options by funds: $1.25B | Put options by funds: $999M
13% more funds holding in top 10
Funds holding in top 10: 63 [Q3] → 71 (+8) [Q4]
5% more capital invested
Capital invested by funds: $147B [Q3] → $155B (+$7.72B) [Q4]
5% more funds holding
Funds holding: 2,856 [Q3] → 2,992 (+136) [Q4]
3.21% more ownership
Funds ownership: 74.27% [Q3] → 77.48% (+3.21%) [Q4]
3% less repeat investments, than reductions
Existing positions increased: 1,109 | Existing positions reduced: 1,148
Research analyst outlook
11 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$127
3%
downside
Avg. target
$146
12%
upside
High target
$160
22%
upside
11 analyst ratings
9 positive
82%
2 neutral
18%
0 negative
0%
Raymond James Jayson Bedford 44% 1-year accuracy 12 / 27 met price target | 9%upside $142 | Outperform Maintained | 17 Apr 2025 |
Piper Sandler Adam Maeder 54% 1-year accuracy 7 / 13 met price target | 11%upside $145 | Overweight Reiterated | 17 Apr 2025 |
RBC Capital Shagun Singh 49% 1-year accuracy 33 / 68 met price target | 11%upside $145 | Outperform Maintained | 17 Apr 2025 |
Wells Fargo Lawrence Biegelsen 25% 1-year accuracy 1 / 4 met price target | 12%upside $147 | Overweight Maintained | 17 Apr 2025 |
Morgan Stanley David Lewis 0 / 0 met price target | 3%downside $127 | Equal-Weight Maintained | 17 Apr 2025 |
Financial journalist opinion
Based on 39 articles about ABT published over the past 30 days
Positive
CNBC
7 hours ago
Healthy Returns: Here are the drugmakers with new U.S. investments as Trump's pharma tariffs loom
Tariff threats are fueling a new wave of U.S. manufacturing investments from the pharmaceutical industry.
Positive
Seeking Alpha
1 day ago
Best Dividend Aristocrats For May 2025
Despite a strong start, the Dividend Aristocrats are underperforming the S&P 500 in April, with NOBL down 4.88% and SPY down 1.53%. The best-performing Dividend Aristocrats YTD include Consolidated Edison (+25.65%), Cardinal Health (+17.82%), and Coca-Cola (+16.18%). 33 out of 69 Dividend Aristocrats have announced dividend increases in 2025, with an average growth rate of 4.33%.
Neutral
PRNewsWire
1 day ago
Abbott Integrates Libre's Data with Epic's Electronic Health Record System, Providing Healthcare Professionals Seamless Glucose Monitoring Information
Collaboration brings together FreeStyle Libre® Systems, the world's leading continuous glucose monitoring technology (CGM)1 with Epic, a healthcare software company, to streamline access to CGM data for healthcare organizations Integration empowers U.S. clinicians to enhance patient care by incorporating Libre's data directly into their workflows ABBOTT PARK, Ill., April 29, 2025 /PRNewswire/ -- Abbott (NYSE: ABT), the global leader in continuous glucose monitoring (CGM) biowearable technology1, today announced that it has entered a first-of-its-kind agreement to integrate data from its world-leading1 Libre CGM systems directly into Epic's electronic health record systems in the U.S. The collaboration aims to improve workflow efficiency for providers through Epic's Aura software, which brings health systems together with diagnostics labs and medical device manufacturers.
Positive
Zacks Investment Research
2 days ago
PBH or ABT: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Products sector have probably already heard of Prestige Consumer Healthcare (PBH) and Abbott (ABT). But which of these two companies is the best option for those looking for undervalued stocks?
Positive
The Motley Fool
2 days ago
3 Dividend Stocks to Buy and Hold for the Next Decade
Many income investors would love to have a low-maintenance portfolio that doesn't require constant attention. They'd prefer to buy great stocks and rake in the dividends without any hiccups.
Neutral
PRNewsWire
3 days ago
Abbott Highlights New AVEIR™ Data, Initiates Trial for the Company's Conduction System Pacing Technology
Late-breaking data from Abbott's groundbreaking first-in-human study demonstrated successful implantation of the company's AVEIR Conduction System Pacing (CSP) leadless pacemaker Enrollment has also begun in the ASCEND CSP pivotal clinical trial to evaluate Abbott's investigational CSP Implantable Cardioverter-Defibrillator (ICD) lead Conduction System Pacing is an evolving technique specifically designed to deliver pacing to the left bundle branch area of the heart to restore its natural electrical rhythm SAN DIEGO , April 27, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced late-breaking data from the AVEIR™ Conduction System Pacing (CSP) acute clinical feasibility study, which demonstrated the safety and performance of the investigational AVEIR CSP leadless pacemaker technology. The AVEIR CSP acute clinical feasibility study is the world's first assessment of a leadless pacemaker delivering conduction pacing to the heart's left bundle branch (LBB) area.
Neutral
PRNewsWire
4 days ago
New Clinical Study Data Showcase Long-Term, Sustained Benefits of Abbott's Volt™ PFA System for Patients with AFib
Long-term data from the Volt CE Mark Study show strong results out to 12 months in patients receiving pulsed field ablation (PFA) therapy with the Volt™ PFA System The 12-month results of the Volt CE Mark Study confirm the long-term safety and efficacy of the Volt PFA System The data were presented at the 2025 Heart Rhythm Society (HRS) annual meeting ABBOTT PARK, Ill., April 26, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) has announced new data from its Volt CE Mark Study that show strong safety and efficacy out to 12 months for patients receiving pulsed field ablation (PFA) therapy with the Volt™ PFA System for the treatment of atrial fibrillation (AFib).
Negative
Zacks Investment Research
5 days ago
Tariffs Cast a Shadow on Abbott's 2025 View: Time to Sell ABT Stock?
With certain devices being imported into the United States from overseas, tariff-induced cost pressure is set to rise for Abbott from the third quarter of 2025.
Neutral
Zacks Investment Research
6 days ago
EPD Growth in Emerging Market Supports Abbott Stock Amid Macro Woes
Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
Positive
Zacks Investment Research
1 week ago
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Charts implemented using Lightweight Charts™